Product Name :
Senazodan
Description:
Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
CAS:
98326-32-0
Molecular Weight:
266.30
Formula:
C15H14N4O
Chemical Name:
6-4-[(pyridin-4-yl)amino]phenyl-2,3,4,5-tetrahydropyridazin-3-one
Smiles :
O=C1CCC(=NN1)C1=CC=C(C=C1)NC1=CC=NC=C1
InChiKey:
XEBRQQXYWHMEQW-UHFFFAOYSA-N
InChi :
InChI=1S/C15H14N4O/c20-15-6-5-14(18-19-15)11-1-3-12(4-2-11)17-13-7-9-16-10-8-13/h1-4,7-10H,5-6H2,(H,16,17)(H,19,20)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.|Product information|CAS Number: 98326-32-0|Molecular Weight: 266.30|Formula: C15H14N4O|Chemical Name: 6-4-[(pyridin-4-yl)amino]phenyl-2,3,4,5-tetrahydropyridazin-3-one|Smiles: O=C1CCC(=NN1)C1=CC=C(C=C1)NC1=CC=NC=C1|InChiKey: XEBRQQXYWHMEQW-UHFFFAOYSA-N|InChi: InChI=1S/C15H14N4O/c20-15-6-5-14(18-19-15)11-1-3-12(4-2-11)17-13-7-9-16-10-8-13/h1-4,7-10H,5-6H2,(H,16,17)(H,19,20)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 25 mg/mL (93.88 mM; ultrasonic and warming and heat to 60°C).Lansoprazole supplier |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Rifampicin Immunology/Inflammation |Shelf Life: ≥12 months if stored properly.PMID:32985253 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhances Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III. Senazodan (0.1 nM~0.1 mM) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca2+ is shifted to the right as compared with Ang II-alone group.|In Vivo:|Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) decreases the pressor effect of norepinephrine (NE). Senazodan (0.1 mg/kg; i.v.) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably.|Products are for research use only. Not for human use.|
